Baseline prostate health index risk category and risk category changes during active surveillance predict grade reclassification
-
Published:2023-11
Issue:11
Volume:41
Page:455.e1-455.e6
-
ISSN:1078-1439
-
Container-title:Urologic Oncology: Seminars and Original Investigations
-
language:en
-
Short-container-title:Urologic Oncology: Seminars and Original Investigations
Author:
de la Calle Claire M.ORCID,
Jing Yuezhou,
Mamawala Mufaddal M.,
Landis Patricia,
Macura Katarzyna J.,
Trock Bruce J.,
Epstein Jonathan I.,
Sokoll Lori J.,
Pavlovich Christian P.ORCID
Reference27 articles.
1. Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging and risk-based management;Eastham;J Urol,2022
2. Clinically localized prostate cancer: AUA/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up;Eastham;J Urol,2022
3. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protect randomised controlled trial according to treatment received;Neal;Eur Urol,2020
4. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer;Hamdy;N Engl J Med,2023
5. 20-year outcomes following conservative management of clinically localized prostate cancer;Albertsen;JAMA,2005
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献